Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type 1 Diabetes AND Diabetes AND Home glucose monitoring

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Type 1 Diabetes AND Diabetes AND Home glucose monitoring. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-002047-92 Sponsor Protocol Number: Birdsong Start Date*: 2007-01-31
    Sponsor Name:Newcastle Primary Care Trust
    Full Title: A multicentre, open-label, randomized comparison of once daily insulin detemir given pre-breakfast or bedtime, according to need, with bedtime insulin glargine in people with type 2 diabetes charac...
    Medical condition: Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018979-16 Sponsor Protocol Number: SAXA24011980GLIPTIN Start Date*: 2010-08-23
    Sponsor Name:University Hospital Erlangen
    Full Title: EFFECTS OF SAXAGLITPIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES
    Medical condition: diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002711-41 Sponsor Protocol Number: VER7200410 Start Date*: 2008-08-15
    Sponsor Name:University of Dundee (Research & Innovation Services)
    Full Title: “Tight glycaemic control” and the risk of hypoglycaemia: Is this different between multiple injections versus insulin pump therapy? A UK multi-centre, open randomised control trial.
    Medical condition: Type 1 diabetes mellitus in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012609 Diabetes mellitus juvenile onset LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005899-13 Sponsor Protocol Number: GEN-084-OL Start Date*: 2008-06-24
    Sponsor Name:Generex Biotechnology Corp.
    Full Title: A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus
    Medical condition: type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002847-96 Sponsor Protocol Number: DRI6012 Start Date*: Information not available in EudraCT
    Sponsor Name:Sanofi aventis US Inc.
    Full Title: A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabe...
    Medical condition: The current study is designed to confirm the already observed clinically meaningful pharmacodynamic effect of AVE0010 on glycemic control, as measured by HbA1c, and to determine the clinically rele...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001922-14 Sponsor Protocol Number: 1245.69 Start Date*: 2015-05-27
    Sponsor Name:Boehringer Ingelheim Ltd
    Full Title: A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 5...
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) SE (Completed) FI (Completed) DK (Completed) DE (Completed) NL (Completed) CZ (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003579-38 Sponsor Protocol Number: APIDR_C_02083 Start Date*: 2007-11-13
    Sponsor Name:sanofi-aventis groupe
    Full Title: Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Dia...
    Medical condition: Type I Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) AT (Completed) HU (Completed) IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007146-34 Sponsor Protocol Number: 2008-3-1 Start Date*: 2008-09-02
    Sponsor Name:Steno Diabetes Center
    Full Title: The Anti-Interleukin-1 in Diabetes Action trial
    Medical condition: new-onset Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023198-21 Sponsor Protocol Number: STH15295 Start Date*: 2011-05-25
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: The Relative Effectiveness of Pumps Over MDI and Structured Education.
    Medical condition: Type-1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004434-24 Sponsor Protocol Number: 2008-3-1 Start Date*: 2008-10-13
    Sponsor Name:Steno Diabetes Center
    Full Title: The Anti-Interleukin-1 in Diabetes Action trial
    Medical condition: new-onset Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012594 Diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001557-29 Sponsor Protocol Number: A2171035 Start Date*: 2006-11-24
    Sponsor Name:Pfizer Inc.
    Full Title: A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJE...
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) NL (Completed) IE (Prematurely Ended) AT (Prematurely Ended) FI (Prematurely Ended) FR (Completed) SE (Prematurely Ended) BE (Completed) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015386-30 Sponsor Protocol Number: GLP108486 Start Date*: 2010-01-29
    Sponsor Name:GlaxoSmithKline LLC
    Full Title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002205-40 Sponsor Protocol Number: OTX115495 (DEFEND-1 EU) Start Date*: 2008-08-29
    Sponsor Name:Tolerx, Inc. [...]
    1. Tolerx, Inc.
    2. GlaxoSmithKline
    Full Title: DEFEND-1: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes
    Medical condition: Otelixizumab is being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), with the goal of preserving RBCF in this patient population. There are cu...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007660-41 Sponsor Protocol Number: GLP112753 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline LLC
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared Wi...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001261-40 Sponsor Protocol Number: I2R-MC-BIAN Start Date*: 2012-03-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAN (a) Study: The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: an Open-Label, Randomized, 78 w...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001253-82 Sponsor Protocol Number: I2R-MC-BIAO Start Date*: 2011-12-02
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAO The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: a Double-Blind, Randomized, 52 Week Study ...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) LT (Completed) BE (Completed) ES (Completed) IE (Completed) DK (Completed) GR (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2005-003504-11 Sponsor Protocol Number: A2171063 Start Date*: 2006-01-27
    Sponsor Name:PFIZER,S.A.
    Full Title: A six-month, open-label outpatient, parallel group trial assessing the impact of inhaled insulin (Exubera®) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled o...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.0 10012601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004526-72 Sponsor Protocol Number: 1 Start Date*: 2006-03-02
    Sponsor Name:Addenbrooke's NHS Trust
    Full Title: A randomised controlled study of continuous subcutaneous insulin infusion (CSII) therapy compared to conventional bolus insulin treatment in preschool aged children with Type 1 diabetes.
    Medical condition: Type 1 Diabetes Mellitus
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000842-39 Sponsor Protocol Number: I2R-MC-BIAJ Start Date*: 2011-10-26
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAJ (a) A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin Naïve Patients with Type 2 ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GB (Completed) CZ (Completed) DE (Completed) LT (Completed) ES (Completed) GR (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000031-26 Sponsor Protocol Number: R256918DIA2001 Start Date*: 2007-12-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) NL (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 22:07:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA